Abstract Number: 1015 • 2015 ACR/ARHP Annual Meeting
Contribution of TNF and Type I Interferon to the Development of Persistent Post-Inflammatory Mechanical Allodynia in Arthritic Mice
Background/Purpose: Male C57Bl/6 (WT) mice develop transient inflammation in response to K/BxN serum transfer and show a corresponding pain state, which persists beyond the resolution…Abstract Number: 1021 • 2015 ACR/ARHP Annual Meeting
Nucleic Acids Sensing Receptors RIG-I and MDA5 As Potential Amplifiers of the Interferon Signature in Childhood Onset Systemic Lupus Erythematosus
Background/Purpose: Defective or sustained activation of Interferon (IFN) signaling has been associated with enhanced susceptibility to systemic lupus erythematosus (SLE). The cytosolic RIG-I-like receptors (RLRs),…Abstract Number: 1098 • 2015 ACR/ARHP Annual Meeting
Interleukin-1 Reciprocally Regulates Interferon-Gamma Induced B Cell Activating Factor of the Tumor Necrosis Factor Family (BAFF) and Interleukin-6 in Human Synovial Fibroblasts
Background/Purpose: B cell activating factor of the tumor necrosis factor family (BAFF) and interleukin-6 (IL-6) are cytokines important for the stimulation and survival of autoreactive…Abstract Number: 1251 • 2015 ACR/ARHP Annual Meeting
Physiological Evidence for Diversification of the IFNα- or IFNβ-Mediated Response Programs in Different Autoimmune Diseases
Background/Purpose: Presence of a type I interferon (IFN) signature is described for several autoimmune diseases, including systemic lupus erythematosus (SLE), multiple sclerosis (MS), myositis (IIM)…Abstract Number: 1525 • 2015 ACR/ARHP Annual Meeting
Detection of Previous Tuberculosis Infections in Japanese Rheumatoid Arthritis Patients: Comparison of Two Interferon-G Releasing Assays and the Impact of CD4-Positive Lymphocytes
Background/Purpose: We aimed to evaluate the performance of QFT-GIT and T-SPOT.TB assays to predict the risk of latent tuberculosis infection (LTBI) in Japanese rheumatoid arthritis…Abstract Number: 1805 • 2015 ACR/ARHP Annual Meeting
Functional and Mechanistic Characterization of Anifrolumab, a Fully Human, Anti-IFNAR1 Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
Background/Purpose: Increased type I interferon (IFN) activities are associated with the pathogenesis of systemic lupus erythematosus (SLE). Anifrolumab, a fully human, IgG1 κ monoclonal antibody…Abstract Number: 1828 • 2015 ACR/ARHP Annual Meeting
Target Modulation of a Type I Interferon Gene Signature and Pharmacokinetics of Anifrolumab in a Phase IIb Study of Patients with Moderate to Severe Systemic Lupus Erythematosus
Background/Purpose: Anifrolumab is a fully human IgG1 monoclonal antibody directed against subunit 1 of the type I interferon receptor (IFNAR1). Anifrolumab blocks the binding of…Abstract Number: 2072 • 2015 ACR/ARHP Annual Meeting
Mitochondrial Reactive Oxygen Species Modulate Autoimmunity in Systemic Lupus Erythematosus
Background/Purpose: Dysregulation in the formation of neutrophil extracellular traps (NETs) may contribute to modification and externalization of autoantigens and to organ damage in diverse autoimmune…Abstract Number: 2073 • 2015 ACR/ARHP Annual Meeting
Mitochondrial ROS Is a Novel Regulator of Sting-Mediated Type I IFN Production By Governing Extrusion of Oxidized Mitochondrial DNA upon Neutrophil Extracellular Trap Formation.
Background/Purpose: Neutrophil extracellular trap generation (NETosis) is a reactive oxygen species (ROS)-dependent cell death pathway implicated in autoimmune disorders such as systemic lupus erythematosus (SLE).…Abstract Number: 2433 • 2015 ACR/ARHP Annual Meeting
Anti Interferon-Gamma (IFNg) Monoclonal Antibody Treatment in a Child with NLRC4-Related Disease and Severe Hemophagocytic Lymphohistiocytosis (HLH)
Background/Purpose: Animal and humans data suggest that IFNγ plays a pathogenic role in HLH. A pilot trial in primary HLH with NI-0501, an anti-IFNγ monoclonal…Abstract Number: 2471 • 2015 ACR/ARHP Annual Meeting
Increased Muscle Interferon-Gamma Expression Levels in Juvenile Dermatomyositis
Background/Purpose : Juvenile dermatomyositis (JDM) is a rare autoimmune disorder characterized by muscle weakness, skin rashes and other systemic features. The immunopathogenesis of JDM is…Abstract Number: 721 • 2015 ACR/ARHP Annual Meeting
Geographic Differences in Demographics, Clinical Characteristics, and Standard of Care in Multinational Studies of Patients with Moderate to Severe Systemic Lupus Erythematosus
Background/Purpose: Most randomized controlled trials (RCTs) in systemic lupus erythematosus (SLE) include stratification factors to ensure a balanced allocation of subgroups that might respond differently…Abstract Number: 2512 • 2015 ACR/ARHP Annual Meeting
Depot Medroxyprogesterone Acetate Birth Control May Suppress Toll-like Receptor 7-Induced Interferon-Alpha Production By Plasmacytoid Dendritic Cells in Women
Background/Purpose: Female sex steroids are important modulators of autoimmunity. Estrogen appears to favor the development of lupus autoimmunity via activation of adaptive and innate immune…Abstract Number: 801 • 2015 ACR/ARHP Annual Meeting
Artesunate Modulates Atherosclerosis Related Factors through the Inhibition of STAT1
Background/Purpose: While type I interferon (IFN) has been linked to atherosclerosis progression in systemic lupus erythematosus (SLE), little is known about its regulation and intervention.…Abstract Number: 2934 • 2015 ACR/ARHP Annual Meeting
Endothelial Dysfunction in SLE-the Role of Platelets and Type I Interferon
Background/Purpose: Type I interferon (IFN) may affect endothelial progenitor cells leading to endothelial dysfunction in SLE. SLE patients have a type I IFN signature in…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 10
- Next Page »